0
0
A groundbreaking study from Colombia, published in India’s premier peer-reviewed journal, reveals that vitamin D deficiency significantly worsens dengue fever severity, raising urgent questions for India where both conditions plague millions. Researchers found patients with severe dengue had markedly lower vitamin D and elevated inflammatory markers, suggesting a key role for this nutrient in modulating immune responses. This discovery, reported on January 22, 2026, underscores the need for targeted screening and supplementation amid India’s ongoing dengue surges.
Study Key Findings
The Colombian research, detailed in the Indian Journal of Medical Research (IJMR), analyzed serum from nearly 100 lab-confirmed dengue patients stratified by disease severity—mild, with warning signs, or severe—alongside healthy controls. Patients with milder dengue maintained higher vitamin D levels (measured as 25(OH)D), while those progressing to severe forms, including dengue hemorrhagic fever, exhibited significant deficiencies. Notably, miRNA-155—a regulator of immune and inflammatory pathways—increased progressively with severity, showing an inverse correlation with vitamin D; low vitamin D also tied to spikes in pro-inflammatory cytokines like TNF-alpha and IL-6, fueling the “cytokine storm” that drives complications.
This builds on prior evidence: A 2025 Indian pediatric study of 280 cases found vitamin D sufficiency protective against progression from dengue fever to severe dengue. Similarly, a Singapore cohort linked low 25(OH)D to heightened bleeding risks independent of low platelets. The IJMR authors propose vitamin D’s antiviral and immunomodulatory effects—curbing viral replication in cells and balancing Th1/Th2 responses—may mitigate these risks.
Dengue and Vitamin D in India
India grapples with a massive dengue burden, with provisional National Centre for Vector Borne Disease Control (NCVBDCP) data showing 193,245 cases and 346 deaths up to late 2025, following 233,519 cases and 297 deaths in 2024. Monsoon spikes overwhelm hospitals, as seen in states like Odisha (7,548 cases) and Punjab (23,389). Vitamin D deficiency compounds this: A Metropolis Healthcare analysis of over 2.2 million tests (2019-2025) found 46.5% deficient and 26% insufficient nationwide, peaking at 51.6% in South India.
Urbanization, indoor lifestyles, pollution, and dietary gaps—despite abundant sunlight—drive this “silent epidemic,” affecting all ages and regions. In dengue hotspots like Delhi and Uttar Pradesh, where cases topped thousands by mid-2025, overlapping deficiencies could amplify severe outcomes.
Expert Perspectives
Dr. R. Goswami, Professor of Endocrinology at AIIMS, New Delhi, hailed the study for elucidating mechanisms via miRNA-155 and Th1/Th2 dysregulation: “It strengthens evidence linking low vitamin D to severe dengue hemorrhagic fever; maintaining normal levels is prudent.” Dr. Pankaj Soni, Principal Director of Internal Medicine at Fortis Escorts Heart Institute, noted clinical parallels: “Low vitamin D worsens inflammation and viral replication, acting as a modifiable risk factor—but not a cure.”
Dr. Atul Gogia, Head of Infectious Diseases at Sir Ganga Ram Hospital, emphasized cytokine storms in severe cases: “Correcting deficiency might reduce complications, but we need larger India-specific trials.” These views align with global experts advocating vitamin D’s role without endorsing routine supplementation for dengue treatment.
Public Health Implications
For India’s health system, this means routine vitamin D screening in dengue patients, especially high-risk groups like children and the elderly, could flag severe cases early. Practical steps include safe sun exposure (10-30 minutes midday), fortified foods, or supplements under medical guidance—doses like 4000 IU/day showed promise in lab models for curbing replication. Public campaigns could integrate this with vector control, as perennial transmission fueled by climate shifts demands multifaceted strategies.
Consumers might prioritize annual vitamin D checks, particularly in deficient regions, to bolster immunity against infections like dengue. Policymakers should fund trials testing supplementation’s impact on outcomes, potentially easing hospital burdens.
Limitations and Balanced View
While compelling, the Colombian study is observational with a modest sample (~100 patients), limiting causality claims; confounding factors like nutrition or comorbidities weren’t fully controlled. Experts stress no evidence supports vitamin D as standalone therapy—supportive care remains cornerstone. Larger randomized controlled trials (RCTs) are essential, as prior small studies vary: some Pakistani data showed trends but not statistical significance due to size.
Conflicting reports exist, like Rajasthan’s zero dengue deaths in 2025 despite thousands of cases, attributed to surveillance and prevention—not vitamin D metrics. Over-supplementation risks toxicity, so self-medication is discouraged.
References
-
Economic Times Health. Low Vitamin D may worsen Dengue outcomes. Jan 22, 2026. https://health.economictimes.indiatimes.com/…
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
